BACKGROUND: Stearoyl-coenzyme A desaturase 1 (SCD1) is a well-known enhancer of the metabolic syndrome. The purpose of the present study was to investigate the role of SCD1 in lipoprotein metabolism and atherosclerosis progression. METHODS AND RESULTS: Antisense oligonucleotides were used to inhibit SCD1 in a mouse model of hyperlipidemia and atherosclerosis (LDLr(-/-)Apob(100/100)). In agreement with previous reports, inhibition of SCD1 protected against diet-induced obesity, insulin resistance, and hepatic steatosis. Unexpectedly, however, SCD1 inhibition strongly promoted aortic atherosclerosis, which could not be reversed by dietary oleate. Further analyses revealed that SCD1 inhibition promoted accumulation of saturated fatty acids in plasma and tissues and reduced plasma triglyceride, yet had little impact on low-density lipoprotein cholesterol. Because dietary saturated fatty acids have been shown to promote inflammation through toll-like receptor 4, we examined macrophage toll-like receptor 4 function. Interestingly, SCD1 inhibition resulted in alterations in macrophage membrane lipid composition and marked hypersensitivity to toll-like receptor 4 agonists. CONCLUSIONS: This study demonstrates that atherosclerosis can occur independently of obesity and insulin resistance and argues against SCD1 inhibition as a safe therapeutic target for the metabolic syndrome.
BACKGROUND:Stearoyl-coenzyme A desaturase 1 (SCD1) is a well-known enhancer of the metabolic syndrome. The purpose of the present study was to investigate the role of SCD1 in lipoprotein metabolism and atherosclerosis progression. METHODS AND RESULTS: Antisense oligonucleotides were used to inhibit SCD1 in a mouse model of hyperlipidemia and atherosclerosis (LDLr(-/-)Apob(100/100)). In agreement with previous reports, inhibition of SCD1 protected against diet-induced obesity, insulin resistance, and hepatic steatosis. Unexpectedly, however, SCD1 inhibition strongly promoted aortic atherosclerosis, which could not be reversed by dietary oleate. Further analyses revealed that SCD1 inhibition promoted accumulation of saturated fatty acids in plasma and tissues and reduced plasma triglyceride, yet had little impact on low-density lipoprotein cholesterol. Because dietary saturated fatty acids have been shown to promote inflammation through toll-like receptor 4, we examined macrophage toll-like receptor 4 function. Interestingly, SCD1 inhibition resulted in alterations in macrophage membrane lipid composition and marked hypersensitivity to toll-like receptor 4 agonists. CONCLUSIONS: This study demonstrates that atherosclerosis can occur independently of obesity and insulin resistance and argues against SCD1 inhibition as a safe therapeutic target for the metabolic syndrome.
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Matthew T Flowers; Albert K Groen; Angie Tebon Oler; Mark P Keller; Younjeong Choi; Kathryn L Schueler; Oliver C Richards; Hong Lan; Makoto Miyazaki; Folkert Kuipers; Christina M Kendziorski; James M Ntambi; Alan D Attie Journal: J Lipid Res Date: 2006-09-27 Impact factor: 5.922
Authors: Zhengfan Jiang; Philippe Georgel; Xin Du; Louis Shamel; Sosathya Sovath; Suzanne Mudd; Michael Huber; Christoph Kalis; Simone Keck; Chris Galanos; Marina Freudenberg; Bruce Beutler Journal: Nat Immunol Date: 2005-05-15 Impact factor: 25.606
Authors: C Lawrence Kien; Dwight E Matthews; Matthew E Poynter; Janice Y Bunn; Naomi K Fukagawa; Karen I Crain; David B Ebenstein; Emily K Tarleton; Robert D Stevens; Timothy R Koves; Deborah M Muoio Journal: J Lipid Res Date: 2015-07-08 Impact factor: 5.922
Authors: Jorge M Caviglia; Jenna L Betters; Dianne-Helerie Dapito; Caleb C Lord; Sean Sullivan; Streamson Chua; Terry Yin; Anna Sekowski; Haiyan Mu; Lawrence Shapiro; J Mark Brown; Dawn L Brasaemle Journal: J Lipid Res Date: 2011-08-31 Impact factor: 5.922
Authors: Gwynneth Thomas; Jenna L Betters; Caleb C Lord; Amanda L Brown; Stephanie Marshall; Daniel Ferguson; Janet Sawyer; Matthew A Davis; John T Melchior; Lawrence C Blume; Allyn C Howlett; Pavlina T Ivanova; Stephen B Milne; David S Myers; Irina Mrak; Vera Leber; Christoph Heier; Ulrike Taschler; Jacqueline L Blankman; Benjamin F Cravatt; Richard G Lee; Rosanne M Crooke; Mark J Graham; Robert Zimmermann; H Alex Brown; J Mark Brown Journal: Cell Rep Date: 2013-10-03 Impact factor: 9.423
Authors: Daniel Ferguson; Jun Zhang; Matthew A Davis; Robert N Helsley; Lise-Lotte Vedin; Richard G Lee; Rosanne M Crooke; Mark J Graham; Daniela S Allende; Paolo Parini; J Mark Brown Journal: J Lipid Res Date: 2016-12-10 Impact factor: 5.922
Authors: J Mark Brown; Soonkyu Chung; Janet K Sawyer; Chiara Degirolamo; Heather M Alger; Tam M Nguyen; Xuewei Zhu; My-Ngan Duong; Amanda L Brown; Caleb Lord; Ramesh Shah; Matthew A Davis; Kathryn Kelley; Martha D Wilson; Jennifer Madenspacher; Michael B Fessler; John S Parks; Lawrence L Rudel Journal: Arterioscler Thromb Vasc Biol Date: 2009-10-15 Impact factor: 8.311
Authors: Ebru Erbay; Vladimir R Babaev; Jared R Mayers; Liza Makowski; Khanichi N Charles; Melinda E Snitow; Sergio Fazio; Michelle M Wiest; Steven M Watkins; Macrae F Linton; Gökhan S Hotamisligil Journal: Nat Med Date: 2009-11-29 Impact factor: 53.440